HERON THERAPEUTICS, INC. /DE/ (HRTX) Operating cash flow 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$27.6MFY2025 · since FY2016: -$134.1M → -$27.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.6M | -22.5% |
| FY2024 | -$22.5M | +61.7% |
| FY2023 | -$58.8M | +60.0% |
| FY2022 | -$146.9M | +27.8% |
| FY2021 | -$203.4M | -10.0% |
| FY2020 | -$184.8M | -48.4% |
| FY2019 | -$124.6M | +35.0% |
| FY2018 | -$191.8M | -12.6% |
| FY2017 | -$170.3M | -27.0% |
| FY2016 | -$134.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Gross marginHRTX Operating incomeHRTX Operating marginHRTX Free cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →